Approved by: Pharmacy Council of India, New Delhi.
Affiliated to: Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur
Affiliated to: Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur
LATEST NEWS
Granules (TP 680): Granules indicated a 20% YoY growth in US sales for FY25. The company expects EBITDA margin to improve QoQ and anticipates FY25 EBITDA margin to be ~22-23%. In addition to the shift towards higher formulation sales from its legacy molecules, GRAN is implementing efforts to: 1) build a pipeline in the space of oncology, large volume products, and innovation/tech-based products (enzyme/contract manufacturing), and b) backwards integrate the manufacturing process of its legacy products. This augurs well for sustaining the
Granules (TP 680): Granules indicated a 20% YoY growth in US sales for FY25. The company expects EBITDA margin to improve QoQ and anticipates FY25 EBITDA margin to be ~22-23%. In addition to the shift towards higher formulation sales from its legacy molecules, GRAN is implementing efforts to: 1) build a pipeline in the space of oncology, large volume products, and innovation/tech-based products (enzyme/contract manufacturing), and b) backwards integrate the manufacturing process of its legacy products. This augurs well for sustaining the
Granules (TP 680): Granules indicated a 20% YoY growth in US sales for FY25. The company expects EBITDA margin to improve QoQ and anticipates FY25 EBITDA margin to be ~22-23%. In addition to the shift towards higher formulation sales from its legacy molecules, GRAN is implementing efforts to: 1) build a pipeline in the space of oncology, large volume products, and innovation/tech-based products (enzyme/contract manufacturing), and b) backwards integrate the manufacturing process of its legacy products. This augurs well for sustaining the
Granules (TP 680): Granules indicated a 20% YoY growth in US sales for FY25. The company expects EBITDA margin to improve QoQ and anticipates FY25 EBITDA margin to be ~22-23%. In addition to the shift towards higher formulation sales from its legacy molecules, GRAN is implementing efforts to: 1) build a pipeline in the space of oncology, large volume products, and innovation/tech-based products (enzyme/contract manufacturing), and b) backwards integrate the manufacturing process of its legacy products. This augurs well for sustaining the
